2026 IPO Train Keeps Chugging as AgomAb Therapeutics and SpyGlass Pharma File for Nasdaq Debuts

AgomAb Therapeutics (New York/Belgium-based) and SpyGlass Pharma (California-based) filed for Nasdaq IPOs last week (around January 16, 2026), with AgomAb trading as AGMB on Nasdaq Global Market and SpyGlass as SGP on Nasdaq Global Select Market.1 3 4 5

SpyGlass' lead asset is a Phase III bimatoprost drug pad-intraocular lens system for ocular hypertension and open-angle glaucoma, implanted during cataract surgery; two registrational trials launched July 2025, enrollment completes 2027, NDA planned 2028; IPO funds for trials and launch.1 3

AgomAb's lead asset ontunisertib (AGMB-129), an oral ALK5 inhibitor, in Phase IIa STENOVA for fibrostenosing Crohn’s disease (data H2 2026), Phase IIb to start later 2026; also advancing AGMB-447 for IPF; IPO funds for clinical studies.1 3 6

Other 2026 biopharma IPOs:
Aktis Oncology (traded Jan 9, $318M raised), Veradermics (hair growth), Eikon Therapeutics (cancer); signals reopening IPO window.1 3